
    
      Eligible patients who agree to participate in the clinical trial in writing will be
      administered Cyclosporine 0.1% eye drop(IkervisÂ®) one drop once daily for 12 weeks. Efficacy
      and safety will be evaluated at baseline, 4 weeks, 8 weeks, and 12 weeks.
    
  